Deutsch English Français

Contact

EP1855662

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1855662

EP1855662 - METHODS AND COMPOSITIONS FOR TREATING CANCER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 10.06.2016 Database last updated on 05.10.2024
Most recent event Tooltip	10.06.2016	Application deemed to be withdrawn	published on 13.07.2016 [2016/28]
Applicant(s)	For all designated states Sound Pharmaceuticals Incorporated 4010 Stone Way N., Suite 120 Seattle, WA 98103 / US
	[2007/47]
Inventor(s)	01 / KIL, Jonathan 2509 13th Avenue W Seattle, Washington 98102 / US
	02 / LYNCH, Eric, Daniel 17519 33rd Avenue NE Lake Forest Park, Washington 98155 / US
	[2007/47]
Representative(s)	Hart, Deborah Mary, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	[N/P]
Former [2007/47]	Hart, Deborah Mary, et al Kilburn & Strode 20 Red Lion Street London WC1R 4PJ / GB
Application number, filing date	06737379.5	08.03.2006
	[2007/47]
	WO2006US08201
Priority number, date	US20050661429P	08.03.2005 Original published format: US 661429 P
	[2007/47]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2006096759
	Date:	14.09.2006
	Language:	EN
	[2006/37]
	Type:	A2 Application without search report
	No.:	EP1855662
	Date:	21.11.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 14.09.2006 takes the place of the publication of the European patent application.
	[2007/47]
Search report(s)	International search report - published on:	US	05.04.2007
	(Supplementary) European search report - dispatched on:	EP	25.11.2009
Classification	IPC:	A61K31/095, A61K31/52, A61P35/00	[2009/52]
	CPC:	A61K31/282 (EP,US); A61K31/41 (EP,KR,US); A61K31/337 (EP,US); A61K31/519 (EP,US); A61K31/555 (EP,US); A61P35/00 (EP)
	Former IPC [2007/47]	A61K31/095, A61K31/52
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/47]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	YU	Not yet paid
Title	German:	VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KREBS	[2007/47]
	English:	METHODS AND COMPOSITIONS FOR TREATING CANCER	[2007/47]
	French:	METHODES ET COMPOSITIONS DESTINEES A TRAITER LE CANCER	[2007/47]
Entry into regional phase	20.09.2007	National basic fee paid
	20.09.2007	Search fee paid
	20.09.2007	Designation fee(s) paid
	20.09.2007	Examination fee paid
Examination procedure	20.09.2007	Examination requested [2007/47]
	19.02.2010	Amendment by applicant (claims and/or description)
	14.12.2012	Despatch of a communication from the examining division (Time limit: M04)
	22.04.2013	Reply to a communication from the examining division
	29.09.2015	Despatch of a communication from the examining division (Time limit: M04)
	10.02.2016	Application deemed to be withdrawn, date of legal effect [2016/28]
	07.03.2016	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/28]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 14.12.2012
Fees paid	Renewal fee
	14.03.2008	Renewal fee patent year 03
	13.03.2009	Renewal fee patent year 04
	15.03.2010	Renewal fee patent year 05
	31.08.2011	Renewal fee patent year 06
	21.08.2012	Renewal fee patent year 07
	03.09.2013	Renewal fee patent year 08
	27.08.2014	Renewal fee patent year 09
	27.03.2015	Renewal fee patent year 10
	Penalty fee
	Additional fee for renewal fee
	31.03.2011	06 M06 Fee paid on 31.08.2011
	31.03.2012	07 M06 Fee paid on 21.08.2012
	31.03.2013	08 M06 Fee paid on 03.09.2013
	31.03.2014	09 M06 Fee paid on 27.08.2014
	31.03.2016	11 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO2004080486 ;
		[X]DE3638124 (NATTERMANN A & CIE [DE]) [X] 1-4,9,11,12 * column 1, line 1 - line 7 *;
		[X]WO9202221 (RHONE POULENC RORER GMBH [DE]) [X] 1-4,9-11,13,14,17-23 * page 2, paragraph 2 * * page 4, paragraph 3 - paragraph 4 * * page 5, paragraph 1 * * claims 1-6 *;
		[X]US2003157191 (KIL JONATHAN [US], et al) [X] 1-11,13-23 * page 1, paragraphs 2,5,13 * * page 2, paragraphs 16,18,19 * * page 5, paragraphs 55,57 * * page 6, paragraphs 62,65 * * page 6; examples 2,3 * * claims 3,9 *;
		[X] - BALDEW G S ET AL, "SELECTIVE REDUCTION OF CIS DIAMMINEDICHLOROPLATINUM-II NEPHROTOXICITY BY EBSELEN", CANCER RESEARCH, (1990), vol. 50, no. 21, ISSN 0008-5472, pages 7031 - 7036, XP002555213 [X] 1-4,11-13,18-23 * abstract *
		[A] - DATABASE WPI, 0, Derwent World Patents Index, vol. 2004, no. 68, Database accession no. 2004-699386, XP002555214 & WO2004080486 A 20040923 (null) [A] 5-12,15-23 * abstract *
	International search	[X]WO03045334 (SOUND PHARMACEUTICALS INC [US], et al);
		[Y] - KERN D.H., "Heterogeneity of drug resistance in human breast and ovarian cancers", CANCER JOURNAL FROM SCIENTIFIC AMERICAN, (199801), vol. 4, no. 1, pages 41 - 45, XP008123189

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p